期刊
METABOLISM-CLINICAL AND EXPERIMENTAL
卷 62, 期 9, 页码 1330-1339出版社
W B SAUNDERS CO-ELSEVIER INC
DOI: 10.1016/j.metabol.2013.05.001
关键词
GLP-1 analog pancreatic function; Mixed-meal tolerance test; Postprandial glucose; Postprandial insulin; Postprandial glucagon
资金
- Hoffmann-La Roche
Objective. Loss of pancreatic function is pivotal to the deterioration of fasting and postprandial glycemic control in type 2 diabetes (T2D). We evaluated the effects of a long-acting, human glucagon-like peptide-1 analog, taspoglutide, added to metformin, on pancreatic function and peripheral insulin sensitivity. Materials/methods. We studied 80 T2D patients inadequately controlled [glycosylated hemoglobin (HbA(1c)), 7.0%-9.5%] receiving stable metformin for >= 12 weeks. They were a subset of participants to a phase 2 trial that received also a 240-min mixed-meal tolerance test (MTT) at baseline and study end. Patients received once weekly (QW) sc injection of taspoglutide 5, 10, or 20 mg (n = 21, 19, or 19), or placebo (n = 21), plus metformin, for 8 weeks. We measured postprandial plasma glucose (PPG) and insulin profiles, insulin secretion rate (ISR), oral glucose insulin sensitivity (OGIS) index; beta-cell glucose sensitivity, glucagon/glucose and insulin/glucagon ratios, and insulin sensitivity-to-insulin resistance (or disposition) index. Results. After 8 weeks of treatment, taspoglutide 5, 10, and 20 mg QW doses us. placebo improved mean PPG(0-240 min) (relative change from baseline: -22.1%, -25.9%, and -22.9% vs. -8.1%; P < 0.005) and mean postprandial ISR0-240 min (+14%, +18%, and +23% us. +1%; P < 0.005 vs dose). Taspoglutide at 20 mg QW dose also resulted in improvements from baseline in OGIS, beta-cell glucose sensitivity, glucagon/glucose and insulin/glucagon ratios and the disposition index during the MTT. Conclusion. Taspoglutide QW significantly improved pancreatic function in patients with T2D treated with metformin. (C) 2013 Elsevier Inc. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据